Skip to main content
. 2018 Aug 30;41(12):1397–1410. doi: 10.1007/s40264-018-0707-6

Fig. 2.

Fig. 2

Change in risk for adverse drug reactions in those receiving adalimumab versus placebo in randomized controlled trials